Clinical MS Research Group
Our single objective: to prevent and reverse disability for everyone with multiple sclerosis, neuromyelitis optica and MOG associated disease.
Research Themes
Cambridge Clinical Multiple Sclerosis Research Group is achieving this objective through six themes:
​
-
Personalising Treatments through Big Data and AI
-
Discovering and Proving New Repair therapies
-
Our Visual and MRI Outcome Development Program
-
Studying Children with MS, NMO and related conditions
-
Study ageing in multiple sclerosis
-
Measuring and sustainably addressing healthcare inequalities.
Currently our work is focused on:
-
Improving the availability of data in electonic health records in the UK for MS researchers
-
Using real-world data to answer important questions about how best to use MS therapies
-
Exploring how best to measure remyelination in adults and children with MS
-
Investigating natural remyelination in people with MS
-
Doing clinical trials to identify drugs which promote endogenous remyelination in people with MS
​​
Read more here.
Featured News
CCMR2 Data Collection Complete!
18th March 2025
Today is a momentous day for the Cambridge Clinical Multiple Sclerosis Research Group, as our last patient in the CCMR Two clinical trial is attending their last visit for assessment.
Read more here.
​
CCMSR Contributes To Global MS Database
18th Feb 2025
In exciting news, we recently securely submitted de-identified clinical data from more than 1000 people living with multiple sclerosis in Cambridge to the MSBase Registry.
Continue reading here.
CCMSR Members Celebrated!
4th November 2024
We are excited to announce that two members of our group, Dr Chris McMurran and Dr Jonathon Holland, have been awarded the Vera Down grant. This award is “to assist research into neurological disorders", which Dr McMurran and Dr Holland will be using to support a novel project that will study the association between biological age and remyelination in people living with MS, aiming to identify reasons for remyelination failure and novel approaches to treating people with MS.
Read more here.
​
​
​